LY-404039 is a drug used in scientific research that acts as a selective agonist for the metabotropic glutamate receptor group II subtypes mGluR2 and mGluR3. It has anxiolytic and antipsychotic effects in animal studies, but without causing sedation. Early human trials using a prodrug form of LY-404,039 called LY-214,0023 have also given encouraging results.

LY-404039 is a drug used in scientific research that acts as a selective agonist for the metabotropic glutamate receptor group II subtypes mGluR2 and mGluR3. It has anxiolytic and antipsychotic effects in animal studies, but without causing sedation. Early human trials using a prodrug form of LY-404,039 called LY-214,0023 have also given encouraging results.

LY-404039 is a drug used in scientific research that acts as a selective agonist for the metabotropic glutamate receptor group II subtypes mGluR2 and mGluR3. It has anxiolytic and antipsychotic effects in animal studies, but without causing sedation. Early human trials using a prodrug form of LY-404,039 called LY-214,0023 have also given encouraging results.

LY-404039 is a drug used in scientific research that acts as a selective agonist for the metabotropic glutamate receptor group II subtypes mGluR2 and mGluR3. It has anxiolytic and antipsychotic effects in animal studies, but without causing sedation. Early human trials using a prodrug form of LY-404,039 called LY-214,0023 have also given encouraging results.

LY2157299 is an orally active transforming growth factor beta receptor (TGF-??R) kinase inhibitor.

LY2157299 is an orally active transforming growth factor beta receptor (TGF-??R) kinase inhibitor.

LY2157299 is an orally active transforming growth factor beta receptor (TGF-??R) kinase inhibitor.

LY2157299 is an orally active transforming growth factor beta receptor (TGF-??R) kinase inhibitor.

LY2228820 is a novel and potent p38MAPK inhibitor with potent antiinflammatory activity.

LY2228820 is a novel and potent p38MAPK inhibitor with potent antiinflammatory activity.

LY2228820 is a novel and potent p38MAPK inhibitor with potent antiinflammatory activity.

LY2228820 is a novel and potent p38MAPK inhibitor with potent antiinflammatory activity.

LY2409881 is a potent and selective IKK2 inhibitor with IC50 of 30 nM, >10-fold selectivity over IKK1 and other common kinases.

LY2409881 is a potent and selective IKK2 inhibitor with IC50 of 30 nM, >10-fold selectivity over IKK1 and other common kinases.

LY2409881 is a potent and selective IKK2 inhibitor with IC50 of 30 nM, >10-fold selectivity over IKK1 and other common kinases.

LY2603618 is a chk2 inhibitor that binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents.

LY2603618 is a chk2 inhibitor that binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents.

LY2603618 is a chk2 inhibitor that binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents.

LY2603618 is a chk2 inhibitor that binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents.

LY2606368 is an inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity.

LY2606368 is an inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity.

LY2606368 is an inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity.

LY2608204 is a potent used to treat type 2 diabetes. In a clinical trial, a study was performed to evaluate the safety and tolerability of LY2608204 in patients with type 2 diabetes.

LY2608204 is a potent used to treat type 2 diabetes. In a clinical trial, a study was performed to evaluate the safety and tolerability of LY2608204 in patients with type 2 diabetes.

LY2608204 is a potent used to treat type 2 diabetes. In a clinical trial, a study was performed to evaluate the safety and tolerability of LY2608204 in patients with type 2 diabetes.

LY2608204 is a potent used to treat type 2 diabetes. In a clinical trial, a study was performed to evaluate the safety and tolerability of LY2608204 in patients with type 2 diabetes.

LY2784544 is identified as being highly selective for JAK2-V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders.

LY2784544 is identified as being highly selective for JAK2-V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders.

LY2784544 is identified as being highly selective for JAK2-V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders.

LY2784544 is identified as being highly selective for JAK2-V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders.

N/A

N/A

LY2795050 is a novel selective ??-opioid Receptor (KOR) antagonist (IC50=0.72 nM) and has the potential as a PET tracer to image KOR in vivo.

LY2795050 is a novel selective ??-opioid Receptor (KOR) antagonist (IC50=0.72 nM) and has the potential as a PET tracer to image KOR in vivo.

LY2795050 is a novel selective ??-opioid Receptor (KOR) antagonist (IC50=0.72 nM) and has the potential as a PET tracer to image KOR in vivo.

LY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.

LY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.

LY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.

LY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound A??-lowering effects in animals.

LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.